Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
sell

Protara Therapeutics Inc. sell stratec

Protara Therapeutics Inc.
Start price
€20.73
28.03.19 / 50%
Target price
€18.04
29.03.19
Performance (%)
0.00%
End price
€18.04
29.03.19
Summary
This prediction ended on 29.03.19 with a price of €18.04. The SELL prediction by stratec closed unchanged from the start price. stratec has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Protara Therapeutics Inc. -1.475% -1.475% 30.469% 63.725%
iShares Core DAX® -1.586% 5.028% 6.332% 64.061%
iShares Nasdaq 100 -4.148% -0.125% 25.735% 86.918%
iShares Nikkei 225® -6.302% 0.528% 41.384% 77.872%
iShares S&P 500 -3.225% 0.470% 20.449% 68.192%

Comments by stratec for this prediction

In the thread Proteon Therapeutics Inc diskutieren
Prediction Sell
Perf. (%) 0.00%
Target price 0.451
Change
Ends at 29.03.19

Proteon's vonapanitase flunks second late-stage study

A Phase 3 clinical trial, PATENCY-2, evaluating Proteon Therapeutics' (NASDAQ:PRTO)

  •  vonapanitase in chronic kidney disease (CKD) patients undergoing the creation of a radiocephalic fistula (vascular access in the wrist area) for hemodialysis failed to beat placebo.




    • stratec 
    0
    Report Share
    28.03.19
    Prediction Sell
    Perf. (%) 0.00%
    Target price 0.451
    Change
    Ends at 29.03.19

    (Zielkurs erreicht)

    stratec 
    0
    Report Share
    29.03.19